Drug Development and PET-Diagnostics for Alzheimers Disease

Author(s): Boris Schmidt, Hannes A. Braun, Rajeshwar Narlawar

Journal Name: Current Medicinal Chemistry

Volume 12 , Issue 14 , 2005

Become EABM
Become Reviewer


The exact cause of Alzheimers disease is still unknown; despite the dramatic progress in understanding. Most gene mutations associated with Alzheimers disease point to the amyloid precursor protein and amyloid β. The α-, β- and γ-secretases are the three executioners of amyloid precursor protein processing. Significant progress has been made in the selective inhibition of these proteases, regardless of the availability of structural information. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical trials. Cholesterol lowering drugs and metal chelators are also in advanced clinical stages as disease modifiers. Successful trials demand either large cohorts or reliable markers for Alzheimers disease. Therefore, several radiomarkers are under investigation to support such clinical trials.

Keywords: alzheimers disease, secretase, copper, statine, aspartic protease, cholesterol, imaging

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [1677 - 1695]
Pages: 19
DOI: 10.2174/0929867054367130
Price: $65

Article Metrics

PDF: 4